Anaptysbio (ANAB) Share-based Compensation (2016 - 2026)

Anaptysbio has reported Share-based Compensation for 11 years, with the latest figure at $14.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 55.05% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $41.1 million (up 24.28% YoY), and the FY2025 full-year result was $36.1 million, up 5.94% from the prior year.
• Share-based Compensation for Q1 2026 stood at $14.2 million, up from $8.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $14.2 million in Q1 2026, with the low at $2.9 million in Q2 2022.
• Historically, Share-based Compensation has averaged $7.5 million across 5 years, with a median of $8.2 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 31.26% — and 2024, when it soared 172.97%.
• Anaptysbio's Share-based Compensation stood at $6.7 million in 2022, then increased by 21.33% to $8.1 million in 2023, then grew by 0.9% to $8.2 million in 2024, then increased by 3.93% to $8.5 million in 2025, then soared by 67.15% to $14.2 million in 2026.
• The last three Share-based Compensation figures came in at $14.2 million (Q1 2026), $8.5 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.